North America Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Labor

North America Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services) 

The North America cervical cancer diagnostic testing market is expected to grow from US$ 2,250.53 million in 2021 to US$ 3,159.09 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. Precancerous changes can delay the disease progression, thus offering an extended time window for its treatment. However, due to the lack of awareness or access to diagnostic services, many cases are detected in the later stages of the illness. Human papillomavirus (HPV), typically transmitted through sexual contact, is one of the primary causes of cervical cancer. Out of more than 100 HPV strains reported, 13 are high-risk or carcinogenic strains. The HPV test detects human papillomavirus in cervical cells. The active gene E6 or E7 determines whether an HPV strain is of high risk or low risk. Other screening methods employed in low-resource areas of several countries include HPV DNA testing and visual inspection. Regular cervical screening aids in the early detection of cervical cancer, lowering the mortality rate from the disease. According to National Cancer Institute, most women aged 21-65 should undergo the Pap test while women from the age group 30-65 should undergo the Pap and HPV tests every three years. The HPV test dominates the cervical cancer screening market in terms of revenue. This trend is expected to continue during the forecast period, thereby driving the North America market.

North America, especially the US, is highly affected by the COVID-19 pandemic. The chaotic situation was created in the medical industry across the countries, increased the demand for diagnosing and therapeutic devices have dramatically increased in the hospitals. For instance, the need for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in hospitals across the countries in the region. The FDA has increased its efforts to support people's health and has imposed several guidelines for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Due to the fear of infection of COVID-19, women are hesitating to take cervical cancer tests, such as the PAP test, biopsies, colonoscopy, and others, as it generally requires an actual visit to the healthcare. This trend among the patients is expected to affect the region's cervical cancer diagnostic testing market over the next few years. However, healthcare providers are now offering at-home testing services for the initial diagnosis through point-of-care devices and kits. The market players are actively involved in organic and inorganic developments. Thus, the outbreak of COVID-19 has shown a remarkable impact on market growth in the region.

Based on type, the PAP testing segment led the North America cervical cancer diagnostic testing market in 2020. The Papanicolaou (PAP) test, also known as the PAP smear test, is a medical procedure to diagnose cervical cancer in women. It is among the widely used traditional methods of testing cervical cancer. It involves sampling cells from the patient's cervix. PAP smear offers the patients a more significant possibility to cure cervical cancer. The PAP smear test can detect transformations in the cervical cells that can cause cancer in the future. It is generally done at an intersection with a pelvic exam in women patients older than 30 years. In some cases, it is performed in combination with human papillomavirus (HPV) test. However, the procedure can be discomforting, involving insertion sampling devices in the vaginal cavity. The segment is expected to significantly contribute to the market share due to the wide adoption in several economies across the region.

The overall North America cervical cancer diagnostic testing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the North America cervical cancer diagnostic testing market. The process also serves the purpose of obtaining overview and forecast for the North America cervical cancer diagnostic testing market with respects to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the North America cervical cancer diagnostic testing market. Abbott; BD; Cooper Companies, Inc.; DYSIS Medical Inc; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among a few players operating in the North America cervical cancer diagnostic testing market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cervical cancer diagnostic testing market.   
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies 
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution